Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review

Ryan, John T; Nakayama, Masao; Gleeson, Ian; Mannion, Liam; Geso, Moshi; Kelly, Jennifer; Ng, Sweet Ping; Hardcastle, Nicholas

doi:10.1186/s13014-022-02146-8

Table 3 Survival and toxicity outcomes

From: Functional brain imaging interventions for radiation therapy planning in patients with glioblastoma: a systematic review

Study name	Citations	Functional imaging agent	Intervention aim							Treatment
Study name	Citations	Functional imaging agent	Improve standard RTtarget delineation	Facilitate doseescalation	Facilitate organ at risk sparing	Map recurrence & RT treated volumes	Map functional volumes& RT planning volumes	Map treated functionalvolumes & survival	Map radiomic features& RT volumes	Standard targetvolumes changed	Dose escalation	Functional OAR sparing
Piroth	[34,35,36,37]	F18-FET PET		\(\checkmark\)		\(\checkmark\)		\(\checkmark\)		\(\checkmark\)	\(\checkmark\)
Laouiti	[38]	F18-FET PET	\(\checkmark\)								\(\checkmark\)
Miwa	[39]	F18-FET PET	\(\checkmark\)								\(\checkmark\)
Munck Af Rosenschold	[40, 41]	F18-FET PET	\(\checkmark\)				\(\checkmark\)	\(\checkmark\)		\(\checkmark\)
Lundemann	[42,43,44]	F18-FET PET	\(\checkmark\)			\(\checkmark\)	\(\checkmark\)		\(\checkmark\)	\(\checkmark\)
Poulsen	[45, 46]	F18-FET PET	\(\checkmark\)					\(\checkmark\)		\(\checkmark\)
Vigil	[52, 53]	C11-MET PET		\(\checkmark\)		\(\checkmark\)	\(\checkmark\)	\(\checkmark\)		\(\checkmark\)	\(\checkmark\)
Brinkmann	[59, 61, 61]	F18-FDOPA PET	\(\checkmark\)	\(\checkmark\)			\(\checkmark\)	\(\checkmark\)		\(\checkmark\)	\(\checkmark\)
Kim	[66, 68, 86]	DW MRI & DCE MRI		\(\checkmark\)				\(\checkmark\)			\(\checkmark\)
Wang	[70]	DTI MRI & BOLD MRI			\(\checkmark\)							\(\checkmark\)
Zhang	[71]	DTT MRI	\(\checkmark\)							\(\checkmark\)
Altabella	[72]	DTI MRI					\(\checkmark\)					\(\checkmark\)
Morin	[74]	DW MRI	\(\checkmark\)			\(\checkmark\)	\(\checkmark\)			\(\checkmark\)
Opposits	[76]	BOLD MRI			\(\checkmark\)					\(\checkmark\)
Laprie	[77,78,79,80]	MRSI		\(\checkmark\)							\(\checkmark\)
Mellon	[82]	MRSI		\(\checkmark\)							\(\checkmark\)

Study name	Max dose			Dose fractionation (Gy / fractions)	Toxicity/OAR dose metric	Survival
Study name	BED\(_{2}\) (Gy)	BED\(_{10}\) (Gy)	EQD\(_2\) (Gy)			Median OS Mths	Median PFS Mths	12 Mths OS %	12 Mths PFS %
Piroth	158.4	89.3	74.4	72/30	No grade 3 or 4 toxicity	14.8	7.8	63.6	25.4
Laouiti	158.4	89.3	74.4	72/30	Maximum grade CTCAE acute toxicity was 1 (median), range 0-2			38.4	28.6
Miwa	357	125.8	104.8	68/8		20	13	71.2	52.6
Munck Af Rosenschold	120	72	60	60/30	Plan OAR (brain, brain stem...) receive less dose in PET-image guided-VMAT plans	15	6
Lundemann	120	72	60	60/30		20.7	11.7
Poulsen	120	72	60	60/30		16.5	6.5
Vigil	Not reported but escalated					20	6.7
Brinkmann	172.3	95.3	79.4	76/30	Grade 3 CNS necrosis was noted in 3 patients (4.4%), 1 patient (1.5%) with pre-existing vision dysfunction had Grade 4 optic nerve dysfunction	16	8.7
Kim	168.8	93.8	78.1	75/30	Side effects were similar in incidence to standard therapy	20		90
Wang	120	72	60	60/30	Plan OAR (white matter tracks) received less dose in functionally optimised plan
Zhang	120	72	60	60/30	Thecognition dysfunction was mild and the radiation-induced brain oedema was mild to moderate	17.6		76	66
Altabella	120	72	60	60/30	Plan OAR (white matter structures) received less dose in DTI-optimised plans
Morin	120	72	60	60/30	Plan OAR (hippocampus) received less dose in DW-optimised plans
Opposits	120	72	60	60/30	Reduced dose in the functionally active areas of the brain
Laprie	158.4	89.3	74.4	72/30	SIB plan OAR (brainstem and brain) received lower doses than CRT plans
Mellon	168.8	93.8	78.1	75/30	No observed serious adverse events

BED\(_2\) Biological effective dose (alpha/beta = 2), BED\(_{10}\) Biological effective dose (alpha/beta = 10), EQD\(_2\) Equivalent dose in 2 Gy (alpha/beta = 10), OS Overall survival, PFS Progression free survival, Mths Months, CTCAE Common terminology criteria for adverse events, OAR Organ at risk, SIB Simultaneous -integrated boost, CRT Conformal radiation therapy

Back to article page

ISSN: 1748-717X

Contact us

General enquiries: journalsubmissions@springernature.com

Radiation Oncology

Contact us